The University of Chicago Header Logo

Connection

Gini Fleming to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications Gini Fleming has written about Breast Neoplasms.
Gini Fleming
Connection Strength
4.640
Breast Neoplasms
  1. Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-13.
    View in: PubMed
    Score: 0.321
  2. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2022 06; 33(6):658.
    View in: PubMed
    Score: 0.320
  3. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122.
    View in: PubMed
    Score: 0.231
  4. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 05 10; 34(14):1601-10.
    View in: PubMed
    Score: 0.212
  5. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 04 23; 372(17):1673.
    View in: PubMed
    Score: 0.199
  6. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):145-53.
    View in: PubMed
    Score: 0.173
  7. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):355-63.
    View in: PubMed
    Score: 0.158
  8. Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med. 2007 Jun; 13(5):555-62.
    View in: PubMed
    Score: 0.115
  9. Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
    View in: PubMed
    Score: 0.091
  10. Adjuvant aromatase inhibitors: are we there yet? Cancer. 2003 Nov 01; 98(9):1779-81.
    View in: PubMed
    Score: 0.090
  11. The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83.
    View in: PubMed
    Score: 0.087
  12. Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
    View in: PubMed
    Score: 0.086
  13. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 03 01; 41(7):1376-1382.
    View in: PubMed
    Score: 0.084
  14. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375.
    View in: PubMed
    Score: 0.084
  15. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 01 01; 30(1):27-35.
    View in: PubMed
    Score: 0.079
  16. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021 02 04; 23(1):18.
    View in: PubMed
    Score: 0.074
  17. Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Res Treat. 2021 Feb; 185(3):841-849.
    View in: PubMed
    Score: 0.073
  18. Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients. Cancer. 2021 01 15; 127(2):300-309.
    View in: PubMed
    Score: 0.073
  19. A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance). Cancer. 2021 01 15; 127(2):291-299.
    View in: PubMed
    Score: 0.073
  20. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
    View in: PubMed
    Score: 0.070
  21. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359.
    View in: PubMed
    Score: 0.070
  22. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 04 20; 38(12):1293-1303.
    View in: PubMed
    Score: 0.068
  23. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. Breast Cancer Res. 2019 07 24; 21(1):82.
    View in: PubMed
    Score: 0.067
  24. Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows. J Clin Oncol. 2019 04 10; 37(11):862-866.
    View in: PubMed
    Score: 0.065
  25. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
    View in: PubMed
    Score: 0.062
  26. Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. J Clin Oncol. 1998 Jun; 16(6):2032-7.
    View in: PubMed
    Score: 0.062
  27. Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim. J Oncol Pharm Pract. 2019 Jul; 25(5):1112-1118.
    View in: PubMed
    Score: 0.061
  28. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clin Cancer Res. 2018 07 15; 24(14):3433-3446.
    View in: PubMed
    Score: 0.061
  29. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 03; 148(3):507-514.
    View in: PubMed
    Score: 0.060
  30. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017 Sep 01; 28(9):2225-2232.
    View in: PubMed
    Score: 0.058
  31. Reply to L.B. Marks et al. J Clin Oncol. 2017 04 10; 35(11):1258-1259.
    View in: PubMed
    Score: 0.056
  32. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J Clin Oncol. 2016 12 20; 34(36):4431-4442.
    View in: PubMed
    Score: 0.055
  33. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Ann Surg Oncol. 2017 Jan; 24(1):38-51.
    View in: PubMed
    Score: 0.055
  34. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):e219-e234.
    View in: PubMed
    Score: 0.055
  35. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016 04 26; 114(9):956-64.
    View in: PubMed
    Score: 0.053
  36. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol. 2016 07 01; 34(19):2221-31.
    View in: PubMed
    Score: 0.053
  37. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol. 2016 05 10; 34(14):1584-93.
    View in: PubMed
    Score: 0.052
  38. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat. 2015 Nov; 154(2):275-86.
    View in: PubMed
    Score: 0.051
  39. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58.
    View in: PubMed
    Score: 0.050
  40. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46.
    View in: PubMed
    Score: 0.048
  41. Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment. Pharmacogenet Genomics. 2014 Sep; 24(9):451-8.
    View in: PubMed
    Score: 0.047
  42. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18.
    View in: PubMed
    Score: 0.047
  43. Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. J Clin Neurosci. 2014 Jul; 21(7):1250-1.
    View in: PubMed
    Score: 0.045
  44. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013 Dec; 22(6):1094-100.
    View in: PubMed
    Score: 0.045
  45. Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study. Breast J. 2013 Sep-Oct; 19(5):470-7.
    View in: PubMed
    Score: 0.044
  46. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
    View in: PubMed
    Score: 0.044
  47. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009 Aug 19; 302(7):774-80.
    View in: PubMed
    Score: 0.033
  48. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009 May; 208(5):906-14; discussion 915-6.
    View in: PubMed
    Score: 0.033
  49. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009 Sep; 117(1):83-9.
    View in: PubMed
    Score: 0.032
  50. Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology. 2008 Nov; 17(11):1108-20.
    View in: PubMed
    Score: 0.032
  51. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. J Clin Oncol. 2008 Jun 01; 26(16):2659-65.
    View in: PubMed
    Score: 0.031
  52. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol. 2008 Jul; 19(7):1231-1241.
    View in: PubMed
    Score: 0.030
  53. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat. 2006 Dec; 100(3):301-8.
    View in: PubMed
    Score: 0.027
  54. In response to Dr. Formenti et al. (Int J Radiat Oncol Biol Phys 2005, 63:1275-1276). Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):658.
    View in: PubMed
    Score: 0.026
  55. Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1045-53.
    View in: PubMed
    Score: 0.025
  56. A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. Am J Clin Oncol. 2005 Feb; 28(1):65-9.
    View in: PubMed
    Score: 0.024
  57. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 01; 22(11):2061-8.
    View in: PubMed
    Score: 0.023
  58. Invariant p53 immunostaining in primary and recurrent breast cancer. Eur J Cancer. 2004 Jan; 40(1):28-32.
    View in: PubMed
    Score: 0.023
  59. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003 Jun 15; 21(12):2268-75.
    View in: PubMed
    Score: 0.022
  60. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83.
    View in: PubMed
    Score: 0.021
  61. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer. 2002 Sep 01; 95(5):989-96.
    View in: PubMed
    Score: 0.021
  62. Expedition inspiration consensus 2001. Breast Cancer Res Treat. 2001 Dec; 70(3):213-9.
    View in: PubMed
    Score: 0.020
  63. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer. Clin Breast Cancer. 2001 Jul; 2(2):138-43; discussion 144.
    View in: PubMed
    Score: 0.019
  64. A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Bone Marrow Transplant. 2001 Apr; 27(7):677-81.
    View in: PubMed
    Score: 0.019
  65. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001 Mar 01; 19(5):1539-69.
    View in: PubMed
    Score: 0.019
  66. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
    View in: PubMed
    Score: 0.018
  67. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol. 2000 Jul; 18(14):2710-7.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.